A Round-up of 2016 Clinical Trials

A Round-up of 2016 Clinical Trials

09:15, May 5 2017

By GlobalData

GlobalData provide a summary of the major developments that took place in clinical development in 2016

This whitepaper provides a review of global clinical trials initiated between Jan 1 and Dec 31, 2016. The data for this review were derived from the Clinical Trials Database of GlobalData's Pharma Intelligence Center. The aim of this paper is to provide analyses of the main features of these trials, coupled with quarterly trends where relevant.

GlobalData analyzed the number of trials carried out by industry and non-industry sponsors, and determined the top sponsors and CROs involved in these clinical trials, as well as the top investigational drugs. Non-industry trials outnumbered industry-sponsored trials across the yearly period. Clinical trials were more frequently run in single countries than across multinational regions and the five major therapy areas were: Oncology, Central Nervous System, Cardiovascular, Infectious Disease, and Metabolic Disorders.

Summary of Contents

  • 5 - Global Clinical Trial Landscape in 2016
  • 5 - Introduction
  • 5 - Clinical Trials by Sponsor Type and Phase in 2016
  • 7 - Single-Country and Multinational Clinical Trials in 2016
  • 7 - Average Size of Clinical Trials in 2016
  • 9 - Global Clinical Trials by Therapy Area in 2016
  • 10 - Top Indications for Global Clinical Trials in 2016
  • 11 - Global Clinical Trials in 2016 by Status
  • 12 - Top Sponsors for Global Clinical Trials in 2016
  • 14 - Top Contract Research Organizations Involved in Global Clinical Trials, 2016
  • 14 - Top Drugs Investigated in Global Clinical Trials in 2016
  • 15 - Summary

Download Whitepaper

A Round-up of 2016 Clinical Trials
More Whitepapers